Novel oral immunotherapies to reverse immune tolerance of solid cancers


Seattle, WA


Series A

Web Site

KayoThera, Inc. is an early-stage therapeutics company focused on the development of a new class of cancer immunotherapeutics. KayoThera is developing therapies to treat late-stage and metastatic cancers including breast, lung, pancreatic, colorectal, brain, and sarcomas.  KayoThera’s science is based on research conducted by Mark Esposito, PhD and Yibin Kang, PhD at Princeton University. Dr. Kang, a Warner-Lambert/Parke-Davis Professor of Molecular Biology, and Dr. Esposito, a postdoctoral research associate in the Kang lab, co-founded KayoThera in 2019 to pursue the development of therapies based on their research.

Mark Esposito, PhD
Yibin Kang, PhD